Sector
PharmaceuticalsOpen
₹393.3Prev. Close
₹391.45Turnover(Lac.)
₹1,706.61Day's High
₹405Day's Low
₹364.752 Week's High
₹401.852 Week's Low
₹208Book Value
₹23.79Face Value
₹1Mkt Cap (₹ Cr.)
4,068.22P/E
90.92EPS
4.09Divi. Yield
0.1814 May 2024
12:00 AM
AGM
Announcement Date: 14 May, 2024
31 Jul 2024
12:00 AM
Bonus
14 May 2024
12:00 AM
Dividend
Dividend Amount: 0.25
26 Jul 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 7.26 | 7.26 | 7.26 | 7.26 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 194.11 | 141.88 | 96.06 | 62.68 |
Net Worth | 201.37 | 149.14 | 103.32 | 69.94 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 90.56 | 85.12 | 38.79 | 35.69 |
yoy growth (%) | 6.38 | 119.39 | 8.7 | 9.4 |
Raw materials | -15.37 | -11.33 | -2.15 | -1.48 |
As % of sales | 16.97 | 13.31 | 5.55 | 4.16 |
Employee costs | -7.11 | -6.43 | -4.45 | -4.41 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 40.88 | 31.25 | 4.83 | 4.88 |
Depreciation | -1.73 | -1.36 | -1.14 | -1.11 |
Tax paid | -10.7 | -7.58 | -0.97 | -0.5 |
Working capital | 34.58 | 16.25 | 0.88 | 3.46 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 6.38 | 119.39 | 8.7 | 9.4 |
Op profit growth | 26.67 | 410.27 | 3.15 | -0.1 |
EBIT growth | 30.09 | 512.27 | -0.7 | 5.32 |
Net profit growth | 27.47 | 512.18 | -11.65 | -5.44 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,706.7 | 95.71 | 4,09,218.58 | 753.53 | 0.94 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,595.5 | 79.35 | 1,75,226.52 | 667 | 0.45 | 2,536 | 561.08 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,741.9 | 63.7 | 1,26,637.21 | 551 | 0.16 | 2,567 | 224.34 |
Cipla Ltd CIPLA | 1,554.6 | 24.3 | 1,25,540.69 | 1,303.13 | 1.03 | 4,501.66 | 397.39 |
Dr Reddys Laboratories Ltd DRREDDY | 1,270.3 | 15.39 | 1,06,062.83 | 2,961.2 | 0.63 | 7,788.7 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Non Executive Director
Dinesh S Patel
Managing Director
Sachin D Patel
Independent Non Exe. Director
VIJAY GOPI KISHAN AGARWAL
Independent Non Exe. Director
Kirandeep Madan
Independent Non Exe. Director
Siddharth Y Kusumgar
Company Sec. & Compli. Officer
RAHUL DWARAKA SONI
Independent Director
Hitesh Dharmasinh Gajaria
69/C GIDC Industrial Estate,
Valsad Dist,
Gujarat - 396195
Tel: 91-260-2430027
Website: http://www.gtbl.in
Email: gtblmumbai@gtbl.in; admin@gtbl.co.in
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Compan...
Read More
Reports by Gujarat Themis Biosyn Ltd
What is the Gujarat Themis Biosyn Ltd share price today?
What is the Market Cap of Gujarat Themis Biosyn Ltd?
What is the PE and PB ratio of Gujarat Themis Biosyn Ltd?
What is the 52 Week High and Low of Gujarat Themis Biosyn Ltd?
What is the CAGR of Gujarat Themis Biosyn Ltd?
What is the shareholding pattern of Gujarat Themis Biosyn Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.